Arkolith/Insider Trading/CTNM/Form 4

Stengone Carmine N.

CEO and President, DirectorContineum Therapeutics, Inc. (CTNM) · full profile →Form 4 · filed Feb 26, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$114K
Net Open-Market Flow
-$114K
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 25, 2026Option exercise(M)3K$1.26$3K18K
Feb 25, 2026Sell(S)3K$16.02$43K15K
Feb 24, 2026Option exercise(M)4K$1.26$6K19K
Feb 24, 2026Sell(S)4K$16.02$70K15K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 25, 2026Option exercise(M)3K—$0121K
Feb 24, 2026Option exercise(M)4K—$0124K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001437749-26-005892) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Contineum Therapeutics, Inc.

Build

Ask your agent about CTNM insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001437749-26-005892"
Ask your agent
Use Arkolith to summarize insider buying and selling at Contineum Therapeutics, Inc.
over the last 90 days and cite the filings.